

Aditya Gupta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6541867/publications.pdf>

Version: 2024-02-01

627
papers

26,361
citations

4641

85
h-index

14702

127
g-index

639
all docs

639
docs citations

639
times ranked

10733
citing authors

#	ARTICLE	IF	CITATIONS
1	Onychomycosis in children – review on treatment and management strategies. Journal of Dermatological Treatment, 2022, 33, 1213-1224.	1.1	13
2	Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality. Journal of Dermatological Treatment, 2022, 33, 62-72.	1.1	24
3	Antifungal resistance in superficial mycoses. Journal of Dermatological Treatment, 2022, 33, 1888-1895.	1.1	21
4	Minoxidil: a comprehensive review. Journal of Dermatological Treatment, 2022, 33, 1896-1906.	1.1	56
5	Finasteride for hair loss: a review. Journal of Dermatological Treatment, 2022, 33, 1938-1946.	1.1	17
6	Fungal Skin Infections (Mycology)., 2022, , 77-111.		0
7	Microneedling for Hair Loss. Journal of Cosmetic Dermatology, 2022, 21, 108-117.	0.8	19
8	Natural products for male androgenetic alopecia. Dermatologic Therapy, 2022, 35, e15323.	0.8	13
9	The effect of placebo in split-scalp and whole-head platelet-rich plasma trials for androgenetic alopecia differs: Findings from a systematic review with quantitative evidence syntheses. Journal of Cosmetic Dermatology, 2022, 21, 1454-1463.	0.8	3
10	Tinea capitis: An update. Pediatric Dermatology, 2022, 39, 167-172.	0.5	12
11	Onychomycosis in Older Adults: Prevalence, Diagnosis, and Management. Drugs and Aging, 2022, 39, 191-198.	1.3	14
12	Relative Efficacy of Minoxidil and the 5- α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients. JAMA Dermatology, 2022, 158, 266.	2.0	35
13	Efinaconazole in Onychomycosis. American Journal of Clinical Dermatology, 2022, 23, 207-218.	3.3	5
14	Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative?. Journal of Cosmetic Dermatology, 2022, 21, 1841-1848.	0.8	7
15	From the Cochrane library: Topical and device-based treatments for fungal infections of the toenails. Journal of the American Academy of Dermatology, 2022, 86, e221-e222.	0.6	1
16	Diagnosing onychomycosis: A step forward?. Journal of Cosmetic Dermatology, 2022, 21, 530-535.	0.8	3
17	Review of the alternative therapies for onychomycosis and superficial fungal infections: posaconazole, fosravuconazole, voriconazole, oteseconazole. International Journal of Dermatology, 2022, 61, 1431-1441.	0.5	9
18	Diagnosing Onychomycosis: What's New?. Journal of Fungi (Basel, Switzerland), 2022, 8, 464.	1.5	11

#	ARTICLE	IF	CITATIONS
19	Utility of polymerase chain reaction for assessment of onychomycosis during topical therapy. <i>International Journal of Dermatology</i> , 2022, 61, 1385-1389.	0.5	7
20	Potential use of microwave technology in dermatology. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2899-2910.	1.1	3
21	Hair loss treatment and restoration: Online interest trends and video-based social media content. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 5902-5909.	0.8	2
22	There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. <i>Skin Appendage Disorders</i> , 2022, 8, 355-361.	0.5	6
23	Meta-analysis of 308-nm excimer laser therapy for alopecia areata. <i>Journal of Dermatological Treatment</i> , 2021, 32, 526-529.	1.1	10
24	Meta-analysis of photobiomodulation for the treatment of androgenetic alopecia. <i>Journal of Dermatological Treatment</i> , 2021, 32, 643-647.	1.1	15
25	Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 95-104.	0.6	14
26	Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1140-1142.	0.6	8
27	Systemic Antifungal Agents. , 2021, , 99-113.e4.		2
28	Topical Antifungal Agents. , 2021, , 480-492.e5.		1
29	Hair loss treatment information on Facebook: Content analysis and comparison with other online sources. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 577-583.	0.8	6
30	The shifting preferences of patients and physicians in nonsurgical hair loss treatment. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 929-936.	0.8	7
31	Continuous terbinafine and pulse itraconazole for the treatment of non-dermatophyte mold toenail onychomycosis. <i>Journal of Dermatological Treatment</i> , 2021, 32, 310-313.	1.1	6
32	Onychomycosis in the Twenty-First Century: An Update on Epidemiology and Diagnosis. , 2021, , 41-64.		1
33	A Paradigm Shift in the Treatment and Management of Onychomycosis. <i>Skin Appendage Disorders</i> , 2021, 7, 351-358.	0.5	18
34	Platelet-Rich Plasma for Hair Loss. , 2021, , 71-82.		21
35	Artificial hair implantation for hair restoration. <i>Journal of Dermatological Treatment</i> , 2021, , 1-7.	1.1	1
36	How good is artificial intelligence (AI) at solving hairy problems? A review of AI applications in hair restoration and hair disorders. <i>Dermatologic Therapy</i> , 2021, 34, e14811.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Preview long hair follicular unit excision: An up–coming technique. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 3422-3426.	0.8	5
38	The increasing problem of treatment–resistant fungal infections: a call for antifungal stewardship programs. <i>International Journal of Dermatology</i> , 2021, 60, e474-e479.	0.5	16
39	Nondermatophyte mould onychomycosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1628-1641.	1.3	25
40	Management of tinea capitis in Israel: A comparative study. <i>Pediatric Dermatology</i> , 2021, 38, 806-811.	0.5	5
41	More than Nail Deep: The Effect of Efinaconazole 10% Treatment on the Quality of Life in Patients with Onychomycosis: A post hoc Study. <i>Skin Appendage Disorders</i> , 2021, 7, 272-279.	0.5	3
42	Hair transplantation Follicular Unit Excision (FUE): Introducing the multipurpose octagonal ring punch. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 2602-2605.	0.8	3
43	Efficacy of non-surgical monotherapies for hidradenitis suppurativa: a systematic review and network meta-analyses of randomized trials. <i>Journal of Dermatological Treatment</i> , 2021, , 1-32.	1.1	4
44	Low–dose isotretinoin versus minocycline in the treatment of rosacea. <i>Dermatologic Therapy</i> , 2021, 34, e14986.	0.8	4
45	Five–year efficacy and safety of tildrakizumab in patients with moderate–to–severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*. <i>British Journal of Dermatology</i> , 2021, 185, 323-334.	1.4	55
46	Fungal Lung: The Risk of Fungal Exposure to Nail Care Professionals. <i>Journal of the American Podiatric Medical Association</i> , 2021, , .	0.2	1
47	Efinaconazole topical solution (10%) for the treatment of onychomycosis in adult and pediatric patients. <i>Expert Review of Anti-Infective Therapy</i> , 2021, , 1-13.	2.0	2
48	One size does not fit all: the need for individualized treatment based on factors that may affect the therapeutic outcome of efinaconazole 10% solution for the treatment of toenail onychomycosis. <i>International Journal of Dermatology</i> , 2021, 60, 1296-1302.	0.5	6
49	Platelet-rich Plasma and Cell Therapy. <i>Dermatologic Clinics</i> , 2021, 39, 429-445.	1.0	11
50	Efficacy of lasers for the management of dermatophyte toenail onychomycosis. <i>Journal of the American Podiatric Medical Association</i> , 2021, , .	0.2	3
51	Cannabinoids for skin diseases and hair regrowth. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 2703-2711.	0.8	15
52	New Antifungal Agents and New Formulations Against Dermatophytes. , 2021, , 433-471.		0
53	The Growing Problem of Antifungal Resistance in Onychomycosis and Other Superficial Mycoses. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 149-157.	3.3	49
54	Monotherapy for toenail onychomycosis: a systematic review and network meta–analysis. <i>British Journal of Dermatology</i> , 2020, 182, 287-299.	1.4	28

#	ARTICLE	IF	CITATIONS
55	The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 580-588.	1.3	13
56	Pathogenesis, Clinical Signs and Treatment Recommendations in Brittle Nails: A Review. <i>Dermatology and Therapy</i> , 2020, 10, 15-27.	1.4	22
57	High prevalence of mixed infections in global onychomycosis. <i>PLoS ONE</i> , 2020, 15, e0239648.	1.1	32
58	An elevated leg movement index during sleep in atopic dermatitis and periodic leg movement disorder may be an indication of sympathetic activation common to both. <i>Journal of Clinical Sleep Medicine</i> , 2020, 16, 463-463.	1.4	1
59	Once Weekly Application of Urea 40% and Bifonazole 1% Leads to Earlier Nail Removal in Onychomycosis. <i>Skin Appendage Disorders</i> , 2020, 6, 304-308.	0.5	6
60	Platelet-rich plasma for androgenetic alopecia: Efficacy differences between men and women. <i>Dermatologic Therapy</i> , 2020, 33, e14143.	0.8	16
61	Factors influencing the effect of photobiomodulation in the treatment of androgenetic alopecia: A systematic review and analyses of summary-level data. <i>Dermatologic Therapy</i> , 2020, 33, e14191.	0.8	5
62	Changing trends in surgical hair restoration: Use of Google Trends and the ISHRS practice census survey. <i>Journal of Cosmetic Dermatology</i> , 2020, 19, 2974-2981.	0.8	12
63	Analysis of YouTube hair loss treatment information: What makes for engaging content?. <i>Dermatologic Therapy</i> , 2020, 33, e14244.	0.8	6
64	A network meta-analysis on the efficacy and safety of monotherapies for tinea capitis, and an assessment of evidence quality. <i>Pediatric Dermatology</i> , 2020, 37, 1014-1022.	0.5	15
65	Response to Raschi E et al. 'Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction'. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e431-e432.	1.3	0
66	Labeled use of efinaconazole topical solution 10% in treating onychomycosis in children and a review of the management of pediatric onychomycosis. <i>Dermatologic Therapy</i> , 2020, 33, e13613.	0.8	5
67	Innovations hair restoration surgeons have made to adapt to the challenges of follicular unit excision. <i>Journal of Cosmetic Dermatology</i> , 2020, 19, 1883-1891.	0.8	14
68	Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e803-e805.	1.3	6
69	Onychomycosis: a review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1972-1990.	1.3	148
70	The edge out punch: An advancement that reduces transections in follicular unit excision hair transplantation. <i>Journal of Cosmetic Dermatology</i> , 2020, 19, 2194-2200.	0.8	4
71	Google search trends in onychomycosis: Influences of flip flops and advertising. <i>Journal of Cosmetic Dermatology</i> , 2020, 19, 2736-2744.	0.8	0
72	Topical and device-based treatments for fungal infections of the toenails. <i>The Cochrane Library</i> , 2020, 1, CD012093.	1.5	21

#	ARTICLE	IF	CITATIONS
73	A Step Toward Standardizing Clinical Trials of Actinic Keratosis. <i>JAMA Dermatology</i> , 2020, 156, 255.	2.0	3
74	Reduced risk of suicidal behaviours associated with the treatment of hidradenitis suppurativa with tumour necrosis factor alpha antagonists: results from the <scp>US FDA</scp> Adverse Events Reporting System pharmacovigilance database. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1564-1568.	1.3	6
75	Follicular Unit Excision Punches and Devices. <i>Dermatologic Surgery</i> , 2020, 46, 1705-1711.	0.4	11
76	Results of the First COVID Impact Member Survey. <i>International Society of Hair Restoration Surgery</i> , 2020, 30, 91.2-91.	0.1	1
77	Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients. <i>Journal of Drugs in Dermatology</i> , 2020, 19, 867-872.	0.4	7
78	Sleep/wake detection by behavioral response to haptic stimuli may be confounded by the sleep stage during which the haptic stimuli are delivered. <i>Journal of Clinical Sleep Medicine</i> , 2020, 16, 823-823.	1.4	1
79	Trichophyton rubrum DNA Strains in Patients with Onychomycosis with Persistent Mixed Infections Involving a Nondermatophyte Mold. <i>Journal of the American Podiatric Medical Association</i> , 2020, 110, .	0.2	3
80	Exosomes: A New Effective Non-Surgical Therapy for Androgenetic Alopecia?. <i>Skinmed</i> , 2020, 18, 96-100.	0.0	3
81	ARAZLO (Tazarotene 0.045%) Lotion for Topical Treatment of Acne Vulgaris. <i>Skinmed</i> , 2020, 18, 102-105.	0.0	0
82	Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System. <i>Skinmed</i> , 2020, 18, 146-150.	0.0	0
83	AKLIEF (Trifarotene 0.005% [50 Î¼g/g] Cream) for Topical Treatment of Acne Vulgaris. <i>Skinmed</i> , 2020, 18, 160-163.	0.0	0
84	A practical application of onychomycosis cure “ combining patient, physician and regulatory body perspectives. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 281-287.	1.3	7
85	Emerging drugs for the treatment of onychomycosis. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 213-220.	1.0	16
86	Recent advances in therapies for onychomycosis and its management. <i>F1000Research</i> , 2019, 8, 968.	0.8	30
87	Fungal Diversity and Onychomycosis. <i>Journal of the American Podiatric Medical Association</i> , 2019, 109, 57-63.	0.2	18
88	Finasteride for androgenetic alopecia is not associated with sexual dysfunction: a survey-based, single-centre, controlled study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1393-1397.	1.3	18
89	Self-induced dermatoses: A great imitator. <i>Clinics in Dermatology</i> , 2019, 37, 268-277.	0.8	26
90	Topical treatments and photodynamic therapy for actinic keratosis of the face and scalp. <i>The Cochrane Library</i> , 2019, , .	1.5	0

#	ARTICLE	IF	CITATIONS
91	The color of skin: psychiatric ramifications. <i>Clinics in Dermatology</i> , 2019, 37, 437-446.	0.8	4
92	Platelet-Rich Plasma as a Treatment for Androgenetic Alopecia. <i>Dermatologic Surgery</i> , 2019, 45, 1262-1273.	0.4	52
93	Global perspectives for the management of onychomycosis. <i>International Journal of Dermatology</i> , 2019, 58, 1118-1129.	0.5	39
94	A Practical Guide to Curing Onychomycosis: How to Maximize Cure at the Patient, Organism, Treatment, and Environmental Level. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 123-133.	3.3	27
95	The Efficacy of Platelet-Rich Plasma in the Field of Hair Restoration and Facial Aesthetics—A Systematic Review and Meta-analysis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 185-203.	0.6	40
96	Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review. <i>Clinical Drug Investigation</i> , 2019, 39, 233-239.	1.1	7
97	Evidence for biofilms in onychomycosis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 50-55.	0.8	38
98	The Role of Shoe and Sock Sanitization in the Management of Superficial Fungal Infections of the Feet. <i>Journal of the American Podiatric Medical Association</i> , 2019, 109, 141-149.	0.2	14
99	Fungal Skin Infections (Mycology). , 2019, , 1-35.		0
100	Dupixent® (Dupilumab): A Newly Approved Interleukin-4 Receptor Antagonist for the Treatment of Atopic Dermatitis in Pediatric Patients. <i>Skinmed</i> , 2019, 17, 107-109.	0.0	0
101	DUOBRIIâ„¢ (Halobetasol Propionate and Tazarotene) Lotion for Topical Use: A Newly Approved Combination Corticosteroid and Retinoid Topical Treatment of Plaque Psoriasis in Adults. <i>Skinmed</i> , 2019, 17, 181-183.	0.0	0
102	Advances in Hair Transplantation Technology: Multiphasic Device for Follicular Unit Excision. <i>Skinmed</i> , 2019, 17, 241-246.	0.0	5
103	The Impact of Onychomycosis on Quality of Life: A Systematic Review of the Available Literature. <i>Skin Appendage Disorders</i> , 2018, 4, 208-216.	0.5	60
104	A Retrospective Study Comparing K101 Nail Solution as a Monotherapy and in Combination with Oral Terbinafine or Itraconazole for the Treatment of Toenail Onychomycosis. <i>Skin Appendage Disorders</i> , 2018, 4, 166-170.	0.5	4
105	Common drug-drug interactions in antifungal treatments for superficial fungal infections. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 387-398.	1.5	21
106	In vitro efficacy of tavaborole topical solution, 5% after penetration through nail polish on ex vivo human fingernails. <i>Journal of Dermatological Treatment</i> , 2018, 29, 633-636.	1.1	8
107	Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies. <i>Journal of Dermatological Treatment</i> , 2018, 29, 44-48.	1.1	13
108	Confirmatory Testing Prior to Initiating Onychomycosis Therapy Is Cost-Effective. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 129-141.	0.6	32

#	ARTICLE	IF	CITATIONS
109	Antibiofilm Treatment for Onychomycosis and Chronic Fungal Infections. <i>Skin Appendage Disorders</i> , 2018, 4, 136-140.	0.5	21
110	Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1373-1376.	1.3	7
111	Update on current approaches to diagnosis and treatment of onychomycosis. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 929-938.	2.0	41
112	Psoriasis Is Associated With a Higher Prevalence of Obstructive Sleep Apnea and Restless Legs Syndrome: A Possible Indication of Autonomic Activation in Psoriasis. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 1085-1085.	1.4	7
113	Examining the Benefits of the Boron-Based Mechanism of Action and Physicochemical Properties of Tavorole in the Treatment of Onychomycosis. <i>Journal of the American Podiatric Medical Association</i> , 2018, 108, 12-19.	0.2	14
114	The Protean <i>Acremonium. A. sclerotigenum/egyptiacum</i> : Revision, Food Contaminant, and Human Disease. <i>Microorganisms</i> , 2018, 6, 88.	1.6	32
115	Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2112-2125.	1.3	68
116	Tinea capitis in children: a systematic review of management. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2264-2274.	1.3	85
117	0917 Finasteride is Associated with a Higher Odds of Obstructive Sleep Apnea (OSA): Results from the US FDA Adverse Events Reporting System (FAERS). <i>Sleep</i> , 2018, 41, A340-A341.	0.6	1
118	Onychomycosis in children: Safety and efficacy of antifungal agents. <i>Pediatric Dermatology</i> , 2018, 35, 552-559.	0.5	28
119	Onychomycosis: Clinical Aspects. , 2018, , 153-159.		3
120	Use of antiepileptic mood stabilizers in dermatology. <i>Clinics in Dermatology</i> , 2018, 36, 756-764.	0.8	14
121	Use of antipsychotic drugs in dermatology. <i>Clinics in Dermatology</i> , 2018, 36, 765-773.	0.8	19
122	Odomzo (Sonidegib). <i>Skinmed</i> , 2018, 16, 35-38.	0.0	2
123	Bavencio (Avelumab)-A Newly Approved Anti-PD-L1 IgG1 Antibody. <i>Skinmed</i> , 2018, 16, 183-187.	0.0	3
124	Ilumya® (Tildrakizumab): A Newly Approved Interleukin-23 Antagonist for the Treatment of Plaque Psoriasis. <i>Skinmed</i> , 2018, 16, 321-324.	0.0	2
125	Cimzia®, (Certolizumab Pegol). <i>Skinmed</i> , 2018, 16, 400-402.	0.0	0
126	Meta-analysis of efficacy of platelet-rich plasma therapy for androgenetic alopecia. <i>Journal of Dermatological Treatment</i> , 2017, 28, 55-58.	1.1	63

#	ARTICLE	IF	CITATIONS
127	Suicidal behaviors in the dermatology patient. Clinics in Dermatology, 2017, 35, 302-311.	0.8	33
128	Dissociation and conversion symptoms in dermatology. Clinics in Dermatology, 2017, 35, 267-272.	0.8	19
129	Obstructive sleep apnea and dermatologic disorders. Clinics in Dermatology, 2017, 35, 319-327.	0.8	12
130	Posttraumatic stress disorder (PTSD) and the dermatology patient. Clinics in Dermatology, 2017, 35, 260-266.	0.8	26
131	A Critical Assessment of the Evidence for Low-Level Laser Therapy in the Treatment of Hair Loss. Dermatologic Surgery, 2017, 43, 188-197.	0.4	34
132	A critical review of improvement rates for laser therapy used to treat toenail onychomycosis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1111-1118.	1.3	38
133	Assessing finasteride-associated sexual dysfunction using the <scp>FAERS</scp> database. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1069-1075.	1.3	27
134	Fungal Skin Infections. Pediatrics in Review, 2017, 38, 8-22.	0.2	13
135	Skin Picking and the Role of Stress. , 2017, , 87-97.		1
136	Topical antifungal treatment prevents recurrence of toenail onychomycosis following cure. Dermatologic Therapy, 2017, 30, e12545.	0.8	19
137	Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment. Journal of Cutaneous Medicine and Surgery, 2017, 21, 525-539.	0.6	168
138	Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review. American Journal of Clinical Dermatology, 2017, 18, 193-213.	3.3	39
139	Treating Alopecia Areata: Current Practices Versus New Directions. American Journal of Clinical Dermatology, 2017, 18, 67-75.	3.3	24
140	Lasers for Onychomycosis. Journal of Cutaneous Medicine and Surgery, 2017, 21, 114-116.	0.6	14
141	Clinical trials of lasers for toenail onychomycosis: The implications of new regulatory guidance. Journal of Dermatological Treatment, 2017, 28, 264-270.	1.1	5
142	New Antifungal Agents and New Formulations Against Dermatophytes. Mycopathologia, 2017, 182, 127-141.	1.3	119
143	Onychomycosis Infections. Journal of the American Podiatric Medical Association, 2017, 107, 280-286.	0.2	25
144	Evaluating the Role of Stress in Skin Disease. , 2017, , 11-17.		2

#	ARTICLE	IF	CITATIONS
145	Ozenoxacin Cream, 1% - Topical Treatment of Impetigo. <i>Skinmed</i> , 2017, 15, 57-59.	0.0	1
146	AMELUZ (BF-200 ALA). <i>Skinmed</i> , 2017, 15, 133-135.	0.0	0
147	Brodalumab (Siliq): A Treatment for Plaque Psoriasis. <i>Skinmed</i> , 2017, 15, 281-285.	0.0	0
148	Crisaborole 2% Ointment (Eucrisa). <i>Skinmed</i> , 2017, 15, 377-380.	0.0	0
149	Bidirectional Relationship between Obstructive Sleep Apnea (OSA) and Psoriasis: Implications for OSA Therapies?. <i>Journal of Clinical Sleep Medicine</i> , 2016, 12, 1309-1309.	1.4	4
150	A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections. <i>Infection and Drug Resistance</i> , 2016, 9, 1.	1.1	26
151	Efficacy of tofacitinib in treatment of alopecia universalis in two patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1373-1378.	1.3	50
152	The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30 000 patients visiting physicians' offices. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1567-1572.	1.3	65
153	Tavaborole "a treatment for onychomycosis of the toenails. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1145-1152.	1.3	28
154	Topical and device-based treatments for fungal infections of the toenails. <i>The Cochrane Library</i> , 2016, , .	1.5	2
155	A Mechanistic Model of Platelet-Rich Plasma Treatment for Androgenetic Alopecia. <i>Dermatologic Surgery</i> , 2016, 42, 1335-1339.	0.4	73
156	An open comparative study of nail drilling as adjunctive treatment for toenail onychomycosis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 480-483.	1.1	26
157	How do we measure efficacy of therapy in onychomycosis: Patient, physician, and regulatory perspectives. <i>Journal of Dermatological Treatment</i> , 2016, 27, 498-504.	1.1	15
158	Topical minocycline foam for moderate to severe acne vulgaris: Phase 2 randomized double-blind, vehicle-controlled study results. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1251-1252.	0.6	23
159	Ergonomics in hair restoration surgeons. <i>Journal of Cosmetic Dermatology</i> , 2016, 15, 66-71.	0.8	17
160	Increased Risk of Tinea Pedis and Onychomycosis Among Swimming Pool Employees in Netanya Area, Israel. <i>Mycopathologia</i> , 2016, 181, 851-856.	1.3	21
161	Improving Cure Rates in Onychomycosis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 517-531.	0.6	19
162	Routes of drug delivery into the nail apparatus: Implications for the efficacy of topical nail solutions in onychomycosis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 2-4.	1.1	18

#	ARTICLE	IF	CITATIONS
163	Novel investigational therapies for onychomycosis: an update. Expert Opinion on Investigational Drugs, 2016, 25, 297-305.	1.9	29
164	The role of biofilms in onychomycosis. Journal of the American Academy of Dermatology, 2016, 74, 1241-1246.	0.6	76
165	How effective is efinaconazole in the management of onychomycosis?. Expert Opinion on Pharmacotherapy, 2016, 17, 611-618.	0.9	16
166	Psoriasis and sleep disorders: A systematic review. Sleep Medicine Reviews, 2016, 29, 63-75.	3.8	110
167	The future of lasers in onychomycosis. Journal of Dermatological Treatment, 2016, 27, 167-172.	1.1	21
168	Onychomycosis: Strategies to Minimize Recurrence. Journal of Drugs in Dermatology, 2016, 15, 279-82.	0.4	27
169	Onychomycosis: Does Cure Equate to Treatment Success?. Journal of Drugs in Dermatology, 2016, 15, 626-32.	0.4	7
170	VALCHLOR (Mechlorethamine) 0.02% Gel. Skinmed, 2016, 14, 120-2.	0.0	0
171	Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa. Skin Therapy Letter, 2016, 21, 1-4.	0.3	3
172	JUBLIA (Efinaconazole): An Update. Skinmed, 2016, 14, 207-9.	0.0	0
173	Topical Treatment of Onychomycosis and Clinically Meaningful Outcomes. Journal of Drugs in Dermatology, 2016, 15, 1260-1266.	0.4	8
174	Adalimumab (Humira) for Hidradenitis Suppurativa. Skinmed, 2016, 14, 291-294.	0.0	0
175	Update on Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis. Skin Therapy Letter, 2016, 21, 7-11.	0.3	2
176	FINACEA (Azelaic Acid) Foam, 15. Skinmed, 2016, 14, 445-447.	0.0	0
177	Evidence- and consensus- based (S3) Guidelines for the Treatment of Actinic Keratosis " International League of Dermatological Societies in cooperation with the European Dermatology Forum " Short version. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2069-2079.	1.3	234
178	Network Meta-Analysis of Onychomycosis Treatments. Skin Appendage Disorders, 2015, 1, 74-81.	0.5	34
179	New and emerging concepts in managing and preventing community-associated methicillin-resistant <i>Staphylococcus aureus</i> infections. International Journal of Dermatology, 2015, 54, 1226-1232.	0.5	17
180	Griseofulvin and Fluconazole Reduce Transmission of Tinea Capitis in Schoolchildren. Pediatric Dermatology, 2015, 32, 696-700.	0.5	6

#	ARTICLE	IF	CITATIONS
181	Antifungal Treatment for Pityriasis Versicolor. Journal of Fungi (Basel, Switzerland), 2015, 1, 13-29.	1.5	48
182	The Rise and Fall of Oral Ketoconazole. Journal of Cutaneous Medicine and Surgery, 2015, 19, 352-357.	0.6	62
183	The prevalence of culture-confirmed toenail onychomycosis in at-risk patient populations. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1039-1044.	1.3	66
184	<i>Trichophyton rubrum</i> DNA strain switching increases in patients with onychomycosis failing antifungal treatments. British Journal of Dermatology, 2015, 172, 74-80.	1.4	19
185	Drug safety assessment of oral formulations of ketoconazole. Expert Opinion on Drug Safety, 2015, 14, 325-334.	1.0	42
186	Dissatisfaction with cutaneous body image is directly correlated with insomnia severity: A prospective study in a non-clinical sample. Journal of Dermatological Treatment, 2015, 26, 193-197.	1.1	18
187	The Relationship Between Dermatologist- and Patient-Reported Acne Severity Measures and Treatment Recommendations. Journal of Cutaneous Medicine and Surgery, 2015, 19, 464-469.	0.6	5
188	Management of Onychomycosis in Canada in 2014. Journal of Cutaneous Medicine and Surgery, 2015, 19, 260-273.	0.6	24
189	Progression of Surgical Hair Restoration Techniques. Journal of Cutaneous Medicine and Surgery, 2015, 19, 17-21.	0.6	9
190	Toenail Onychomycosis- A Canadian Approach With a New Transungual Treatment. Journal of Cutaneous Medicine and Surgery, 2015, 19, 440-449.	0.6	15
191	New pharmacotherapy for the treatment of onychomycosis: an update. Expert Opinion on Pharmacotherapy, 2015, 16, 227-236.	0.9	28
192	A retrospective chart review of the clinical efficacy of Nd:YAG 1064-nm laser for toenail onychomycosis. Journal of Dermatological Treatment, 2015, 26, 376-378.	1.1	24
193	When is onychomycosis onychomycosis? A cross-sectional study of fungi in normal-appearing nails. British Journal of Dermatology, 2015, 172, 380-383.	1.4	15
194	Therapies for Onychomycosis. Journal of the American Podiatric Medical Association, 2015, 105, 357-366.	0.2	20
195	Sinecatechins 10% ointment: a green tea extract for the treatment of external genital warts. Skin Therapy Letter, 2015, 20, 6-8.	0.3	6
196	The Presence of an Air Gap Between the Nail Plate and Nail Bed in Onychomycosis Patients: Treatment Implications for Topical Therapy. Journal of Drugs in Dermatology, 2015, 14, 859-63.	0.4	14
197	Trichotillomania: Demographic and Clinical Features From a Nationally Representative US Sample. Skinmed, 2015, 13, 455-60.	0.0	7
198	OPDIVO (Nivolumab). Skinmed, 2015, 13, 471-4.	0.0	0

#	ARTICLE	IF	CITATIONS
199	Tavaborole 5% Solution: A Novel Topical Treatment for Toenail Onychomycosis. <i>Skin Therapy Letter</i> , 2015, 20, 6-9.	0.3	4
200	Do Genetic Mutations and Genotypes Contribute to Onychomycosis?. <i>Dermatology</i> , 2014, 228, 207-210.	0.9	19
201	Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 735-742.	2.0	26
202	Comparison of visual assessments versus planimetry assessments in a large-scale clinical trial of onychomycosis. <i>Journal of Dermatological Treatment</i> , 2014, 25, 256-259.	1.1	4
203	Efinaconazole 10% Nail Solution. <i>Journal of Cutaneous Medicine and Surgery</i> , 2014, 18, 151-155.	0.6	6
204	Potential role of tavaborole for the treatment of onychomycosis. <i>Future Microbiology</i> , 2014, 9, 1243-1250.	1.0	18
205	Systematic Review of Systemic Treatments for Tinea Versicolor and Evidence-Based Dosing Regimen Recommendations. <i>Journal of Cutaneous Medicine and Surgery</i> , 2014, 18, 79-90.	0.6	32
206	Molecular Determination of Mixed Infections of Dermatophytes and Nondermatophyte Molds in Individuals with Onychomycosis. <i>Journal of the American Podiatric Medical Association</i> , 2014, 104, 330-336.	0.2	37
207	The efficacy and safety of 5 α -reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. <i>Journal of Dermatological Treatment</i> , 2014, 25, 156-161.	1.1	80
208	Ozone gas effectively kills laboratory strains of <i>Trichophyton rubrum</i> and <i>Trichophyton mentagrophytes</i> using an <i>in vitro</i> test system. <i>Journal of Dermatological Treatment</i> , 2014, 25, 251-255.	1.1	18
209	Current Concepts in Psychodermatology. <i>Current Psychiatry Reports</i> , 2014, 16, 449.	2.1	19
210	Systematic Review of Oral Treatments for Seborrheic Dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 16-26.	1.3	51
211	Topical Therapy for Toenail Onychomycosis: An Evidence-Based Review. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 489-502.	3.3	42
212	Increased frequency of Attention Deficit Hyperactivity Disorder (ADHD) in acne versus dermatologic controls: analysis of an epidemiologic database from the US. <i>Journal of Dermatological Treatment</i> , 2014, 25, 115-118.	1.1	22
213	Pityriasis versicolor: an update on pharmacological treatment options. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1707-1713.	0.9	24
214	Investigational drugs for onychomycosis. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 97-106.	1.9	21
215	Efinaconazole (Jublia) for the treatment of onychomycosis. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 743-752.	2.0	8
216	Placebo Cure Rates in the Treatment of Onychomycosis. <i>Journal of the American Podiatric Medical Association</i> , 2014, 104, 277-282.	0.2	3

#	ARTICLE	IF	CITATIONS
217	The use of low-level light therapy in the treatment of androgenetic alopecia and female pattern hair loss. <i>Journal of Dermatological Treatment</i> , 2014, 25, 162-163.	1.1	21
218	Topical Treatment of Onychomycosis as a Realistic Option to Systemic Therapy. <i>Journal of the American Podiatric Medical Association</i> , 2014, 104, 115-117.	0.2	0
219	Efinaconazole: a new topical treatment for onychomycosis. <i>Skin Therapy Letter</i> , 2014, 19, 1-4.	0.3	1
220	The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials. <i>Journal of Drugs in Dermatology</i> , 2014, 13, 815-20.	0.4	20
221	Surgical hair restoration and the advent of a robotic-assisted extraction device. <i>Skinmed</i> , 2014, 12, 213-6.	0.0	1
222	5% Minoxidil: treatment for female pattern hair loss. <i>Skin Therapy Letter</i> , 2014, 19, 5-7.	0.3	19
223	Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild to moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 287-294.	1.3	63
224	Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta-analysis of efficacy for continuous and intermittent regimens. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 267-272.	1.3	57
225	Evidence-based optimal fluconazole dosing regimen for onychomycosis treatment. <i>Journal of Dermatological Treatment</i> , 2013, 24, 75-80.	1.1	41
226	Cutaneous body image dissatisfaction and suicidal ideation: Mediation by interpersonal sensitivity. <i>Journal of Psychosomatic Research</i> , 2013, 75, 55-59.	1.2	32
227	Therapies for the treatment of onychomycosis. <i>Clinics in Dermatology</i> , 2013, 31, 544-554.	0.8	96
228	A practical approach to the assessment of psychosocial and psychiatric comorbidity in the dermatology patient. <i>Clinics in Dermatology</i> , 2013, 31, 57-61.	0.8	24
229	Evaluation of cutaneous body image dissatisfaction in the dermatology patient. <i>Clinics in Dermatology</i> , 2013, 31, 72-79.	0.8	48
230	Sleep-wake disorders and dermatology. <i>Clinics in Dermatology</i> , 2013, 31, 118-126.	0.8	83
231	Meta-Analysis of Randomized, Controlled Trials Comparing Particular Doses of Griseofulvin and Terbinafine for the Treatment of Tinea Capitis. <i>Pediatric Dermatology</i> , 2013, 30, 1-6.	0.5	70
232	Diagnosing onychomycosis. <i>Clinics in Dermatology</i> , 2013, 31, 540-543.	0.8	51
233	Nails and the clinician. <i>Clinics in Dermatology</i> , 2013, 31, 507-508.	0.8	3
234	Systemic Antifungals to Treat Onychomycosis in Children: A Systematic Review. <i>Pediatric Dermatology</i> , 2013, 30, 294-302.	0.5	42

#	ARTICLE	IF	CITATIONS
235	Improved efficacy in onychomycosis therapy. Clinics in Dermatology, 2013, 31, 555-563.	0.8	23
236	Network meta-analysis of the outcome "participant complete clearance"™ in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. British Journal of Dermatology, 2013, 169, 250-259.	1.4	104
237	Sanitization of Contaminated Footwear from Onychomycosis Patients Using Ozone Gas: A Novel Adjunct Therapy for Treating Onychomycosis and Tinea Pedis?. Journal of Cutaneous Medicine and Surgery, 2013, 17, 243-249.	0.6	29
238	Recurrences of Dermatophyte Toenail Onychomycosis during Long-Term Follow-up after Successful Treatments with Mono- and Combined Therapy of Terbinafine and Itraconazole. Journal of Cutaneous Medicine and Surgery, 2013, 17, 201-206.	0.6	26
239	Laser Therapy for Onychomycosis. Journal of Cutaneous Medicine and Surgery, 2013, 17, 301-307.	0.6	18
240	Ingenol Mebutate: A Promising Treatment for Actinic Keratoses and Nonmelanoma Skin Cancers. Journal of Cutaneous Medicine and Surgery, 2013, 17, 173-179.	0.6	26
241	Topical treatments for athlete's foot. The Cochrane Library, 2013, , .	1.5	0
242	Cutaneous Sensory Disorder. Seminars in Cutaneous Medicine and Surgery, 2013, 32, 110-118.	1.6	18
243	ONMEL (itraconazole) 200-mg tablet. Skinmed, 2013, 11, 105-7.	0.0	1
244	Onchomycosis: an overview. Journal of Drugs in Dermatology, 2013, 12, s96-103.	0.4	23
245	Efinaconazole 10% nail solution. Skinmed, 2013, 11, 239-41.	0.0	0
246	Systemic antifungal agents. , 2013, , 98-120.e3.		11
247	Newly Approved Laser Systems for Onychomycosis. Journal of the American Podiatric Medical Association, 2012, 102, 428-430.	0.2	21
248	Medical devices for the treatment of onychomycosis. Dermatologic Therapy, 2012, 25, 574-581.	0.8	29
249	A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. Journal of Dermatological Treatment, 2012, 23, 261-267.	1.1	47
250	Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response. Journal of the American Academy of Dermatology, 2012, 66, 486-493.	0.6	161
251	Systematic review of nondermatophyte mold onychomycosis: Diagnosis, clinical types, epidemiology, and treatment. Journal of the American Academy of Dermatology, 2012, 66, 494-502.	0.6	212
252	Chronic idiopathic urticaria and post-traumatic stress disorder (PTSD): An under-recognized comorbidity. Clinics in Dermatology, 2012, 30, 351-354.	0.8	25

#	ARTICLE	IF	CITATIONS
253	Interventions for actinic keratoses. The Cochrane Library, 2012, 12, CD004415.	1.5	112
254	New therapeutic options for onychomycosis. Expert Opinion on Pharmacotherapy, 2012, 13, 1131-1142.	0.9	77
255	Calcipotriol plus Betamethasone Dipropionate Gel Compared with Tacalcitol Ointment and the Gel Vehicle Alone in Patients with Psoriasis Vulgaris: A Randomized, Controlled Clinical Trial. Dermatology, 2011, 222, 148-156.	0.9	47
256	Development and Validation of a Scale for Acne Scar Severity (SCAR-S) of the Face and Trunk. Journal of Cutaneous Medicine and Surgery, 2010, 14, 156-160.	0.6	42
257	Superficial and subcutaneous fungal pathogens. , 2010, , 1853-1867.		3
258	Onychomycosis therapy: past, present, future. Journal of Drugs in Dermatology, 2010, 9, 1109-13.	0.4	31
259	Zyclara (imiquimod) cream, 3.75%. Skinmed, 2010, 8, 227-9.	0.0	13
260	Psoriatic Nail Disease: Quality of Life and Treatment. Journal of Cutaneous Medicine and Surgery, 2009, 13, S102-S106.	0.6	28
261	Effect of Quality of Life Impact and Clinical Severity on Adherence to Topical Acne Treatment. Journal of Cutaneous Medicine and Surgery, 2009, 13, 204-208.	0.6	23
262	Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. Journal of Pharmaceutical Sciences, 2009, 98, 4130-4140.	1.6	64
263	A Double-Blind, Randomized, Placebo-Controlled Trial of Eutectic Lidocaine/Prilocaine Cream 5% (EMLA)® for Analgesia Prior to Cryotherapy of Warts in Children and Adults. Pediatric Dermatology, 2009, 15, 129-133.	0.5	6
264	Itraconazole Oral Solution for the Treatment of Onychomycosis. Pediatric Dermatology, 2009, 15, 472-474.	0.5	0
265	The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 256-262.	1.3	55
266	<i>In vitro</i> pharmacodynamic characteristics of griseofulvin against dermatophyte isolates of <i>Trichophyton tonsurans</i> from tinea capitis patients. Medical Mycology, 2009, 47, 796-801.	0.3	29
267	Update in Antifungal Therapy of Dermatophytosis. Mycopathologia, 2008, 166, 353-367.	1.3	245
268	Xyzal (levocetirizine dihydrochloride). Skinmed, 2008, 7, 84-85.	0.0	2
269	Diagnosis of <i>Trichophyton rubrum</i> from Onychomycotic Nail Samples Using Polymerase Chain Reaction and Calcofluor White Microscopy. Journal of the American Podiatric Medical Association, 2008, 98, 224-228.	0.2	18
270	Divergence of Demographic Factors Associated with Clinical Severity Compared with Quality of Life Impact in Acne. Journal of Cutaneous Medicine and Surgery, 2008, 12, 235-242.	0.6	51

#	ARTICLE	IF	CITATIONS
271	ISA247: Quality of Life Results from a Phase II, Randomized, Placebo-Controlled Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2008, 12, 268-275.	0.6	18
272	Naftifine: A Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2008, 12, 51-58.	0.6	35
273	Dermatophytosis (Tinea) and Other Superficial Fungal Infections. , 2008, , 355-381.		3
274	Meta-analysis: griseofulvin efficacy in the treatment of tinea capitis. <i>Journal of Drugs in Dermatology</i> , 2008, 7, 369-72.	0.4	32
275	New Therapy Update. <i>Skinmed</i> , 2007, 6, 28-29.	0.0	0
276	Biologic Therapeutics in the Treatment of Psoriasis. Part 1: Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007, 11, 99-122.	0.6	16
277	Position Statement for Isotretinoin. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007, 11, 123-124.	0.6	3
278	Extina Foam (2%). <i>Skinmed</i> , 2007, 6, 186-187.	0.0	0
279	Ziana (Clindamycin Phosphate 1.2% and Tretinoin 0.025%)Gel. <i>Skinmed</i> , 2007, 6, 85-87.	0.0	1
280	Biologic Therapeutics in the Treatment of Psoriasis. Part 2: Practical Considerations. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007, 11, 145-149.	0.6	1
281	Development and Validation of a Comprehensive Acne Severity Scale. <i>Journal of Cutaneous Medicine and Surgery</i> , 2007, 11, 211-216.	0.6	112
282	Systematic review of rosacea treatments. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 107-115.	0.6	78
283	Evaluation of microdilution and disk diffusion methods for antifungal susceptibility testing of dermatophytes. <i>Medical Mycology</i> , 2007, 45, 595-602.	0.3	52
284	Differin (adapalene) Gel, 0.3%. <i>Skinmed</i> , 2007, 6, 287-288.	0.0	0
285	Altabax (retapamulin ointment), 1%. <i>Skinmed</i> , 2007, 6, 239-240.	0.0	2
286	Fast and sensitive detection of <i>Trichophyton rubrum</i> DNA from the nail samples of patients with onychomycosis by a double-round polymerase chain reaction-based assay. <i>British Journal of Dermatology</i> , 2007, 157, 698-703.	1.4	40
287	Azelaic acid (15% gel) in the treatment of acne rosacea. <i>International Journal of Dermatology</i> , 2007, 46, 533-538.	0.5	38
288	Nail Disorders and their Management. <i>Dermatologic Clinics</i> , 2006, 24, ix-x.	1.0	0

#	ARTICLE	IF	CITATIONS
289	Onychomycosis Therapies: Strategies to Improve Efficacy. <i>Dermatologic Clinics</i> , 2006, 24, 381-386.	1.0	13
290	Diagnosing Onychomycosis. <i>Dermatologic Clinics</i> , 2006, 24, 365-369.	1.0	39
291	Therapies for Onychomycosis: A Review. <i>Dermatologic Clinics</i> , 2006, 24, 375-379.	1.0	37
292	Dermatophytes: Diagnosis and treatment. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 1050-1055.	0.6	39
293	The treatment of melasma: A review of clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 1048-1065.	0.6	367
294	Medically unexplained cutaneous sensory symptoms may represent somatoform dissociation: An empirical study. <i>Journal of Psychosomatic Research</i> , 2006, 60, 131-136.	1.2	41
295	Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 1188-1193.	1.3	37
296	Depression Modulates Pruritus Perception: A Study of Pruritus in Psoriasis, Atopic Dermatitis and Chronic Idiopathic Urticaria. <i>Annals of the New York Academy of Sciences</i> , 2006, 885, 394-395.	1.8	37
297	Ciclopirox 1% shampoo for the treatment of seborrheic dermatitis. <i>International Journal of Dermatology</i> , 2006, 45, 66-69.	0.5	29
298	Canadian Perspectives on Antifungal Treatment for Onychomycosis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006, 10, S34-S38.	0.6	2
299	Efalizumab in the Treatment of Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006, 10, 57-68.	0.6	11
300	Multitherapy Approach to Onychomycosis Therapy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006, 10, S44-S47.	0.6	8
301	Pharmacoeconomic Assessment of Ciclopirox Topical Solution, 8%, Oral Terbinafine, and Oral Itraconazole for Onychomycosis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006, 10, S54-S62.	0.6	6
302	Brief Treatment Guide for Onychomycosis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006, 10, S39-S43.	0.6	4
303	New Therapy Update. <i>Skinmed</i> , 2006, 5, 136-138.	0.0	2
304	Solodyn (Minocycline HCl, USP) Extended-Release Tablets. <i>Skinmed</i> , 2006, 5, 291-292.	0.0	2
305	Clobex (clobetasol propionate) Spray, 0.05%. <i>Skinmed</i> , 2006, 5, 184-185.	0.0	0
306	Oracea (doxycycline monohydrate). <i>Skinmed</i> , 2006, 5, 238-240.	0.0	3

#	ARTICLE	IF	CITATIONS
307	Evaluation of the Effectiveness of Imiquimod and 5-Fluorouracil for the Treatment of Actinic Keratosis: Critical Review and Meta-Analysis of Efficacy Studies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005, 9, 209-214.	0.6	30
308	Baillon, emerging clinical yeasts. <i>FEMS Yeast Research</i> , 2005, 5, 1101-1113.	1.1	119
309	A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2005, 19, 437-443.	1.3	62
310	Rosacea and its management: an overview. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2005, 19, 273-285.	1.3	107
311	REPLY TO DIEHL. <i>Pediatric Dermatology</i> , 2005, 22, 372-372.	0.5	0
312	Evaluation of the efficacy of ciclopirox 0.77% gel in the treatment of tinea pedis interdigitalis (dermatophytosis complex) in a randomized, double-blind, placebo-controlled trial. <i>International Journal of Dermatology</i> , 2005, 44, 590-593.	0.5	20
313	Comorbidity of rosacea and depression: an analysis of the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey-Outpatient Department data collected by the U.S. National Center for Health Statistics from 1995 to 2002. <i>British Journal of Dermatology</i> , 2005, 153, 1176-1181.	1.4	94
314	Evaluation of the Effectiveness of Imiquimod and 5-Fluorouracil for the Treatment of Actinic Keratosis: Critical Review and Meta-analysis of Efficacy Studies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005, 9, 209-214.	0.6	87
315	A favourable benefit/risk ratio with efalizumab: A review of the clinical evidence. <i>Journal of Cutaneous Medicine and Surgery</i> , 2005, 9, 10-17.	0.6	83
316	Dermatophytosis: The Management of Fungal Infections. <i>Skinmed</i> , 2005, 4, 305-310.	0.0	58
317	Alefacept: an expert review concerning the treatment of psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2327-2333.	0.9	11
318	In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. <i>Medical Mycology</i> , 2005, 43, 179-185.	0.3	76
319	Depression and Skin Disease. <i>Dermatologic Clinics</i> , 2005, 23, 657-664.	1.0	60
320	Psychiatric Evaluation of the Dermatology Patient. <i>Dermatologic Clinics</i> , 2005, 23, 591-599.	1.0	54
321	Onychomycosis: a critical study of techniques and criteria for confirming the etiologic significance of nondermatophytes. <i>Medical Mycology</i> , 2005, 43, 39-59.	0.3	117
322	Pityriasis versicolor: a review of pharmacological treatment options. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 165-178.	0.9	25
323	Pharmacotherapy of onychomycosis. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 609-624.	0.9	31
324	Fluorouracil Formulations for the Treatment of Actinic Keratosis. <i>American Journal of Cancer</i> , 2005, 4, 115-126.	0.4	0

#	ARTICLE	IF	CITATIONS
325	The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence. <i>Journal of Drugs in Dermatology</i> , 2005, 4, 302-8.	0.4	32
326	Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. <i>Journal of Drugs in Dermatology</i> , 2005, 4, 481-5.	0.4	30
327	Pathogenesis of Psoriasis and Current Challenges. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 3-7.	0.6	3
328	Prevalence of Malassezia species on various body sites in clinically healthy subjects representing different age groups. <i>Medical Mycology</i> , 2004, 42, 35-42.	0.3	58
329	Seborrheic dermatitis: current treatment practices. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1755-1765.	0.9	14
330	Identification and Typing of Malassezia Species by Amplified Fragment Length Polymorphism and Sequence Analyses of the Internal Transcribed Spacer and Large-Subunit Regions of Ribosomal DNA. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4253-4260.	1.8	121
331	Prescribing practices for seborrheic dermatitis vary with the physician's specialty: implications for clinical practice. <i>Journal of Dermatological Treatment</i> , 2004, 15, 208-213.	1.1	12
332	Etiology and Management of Seborrheic Dermatitis. <i>Dermatology</i> , 2004, 208, 89-93.	0.9	107
333	Ciclopirox: a broad-spectrum antifungal with antibacterial and anti-inflammatory properties. <i>International Journal of Dermatology</i> , 2004, 43, 3-8.	0.5	51
334	Ciclopirox 1% shampoo is a safe and effective treatment for seborrheic dermatitis. <i>International Journal of Dermatology</i> , 2004, 43, 1-2.	0.5	0
335	Management of diaper dermatitis. <i>International Journal of Dermatology</i> , 2004, 43, 830-834.	0.5	50
336	Seborrheic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2004, 18, 13-26.	1.3	215
337	Stressful major life events are associated with a higher frequency of cutaneous sensory symptoms: an empirical study of non-clinical subjects. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2004, 18, 560-565.	1.3	54
338	Onychomycosis in Children: A Brief Overview with Treatment Strategies. <i>Pediatric Dermatology</i> , 2004, 21, 74-79.	0.5	50
339	Tinea Capitis in Kwa-Zulu Natal, South Africa. <i>Pediatric Dermatology</i> , 2004, 21, 444-447.	0.5	34
340	Itraconazole in the Treatment of Tinea Capitis Caused by <i>Microsporum canis</i> : Experience in a Large Cohort. <i>Pediatric Dermatology</i> , 2004, 21, 499-502.	0.5	60
341	Cutaneous Body Image: Empirical Validation of a Dermatologic Construct. <i>Journal of Investigative Dermatology</i> , 2004, 123, 405-406.	0.3	22
342	Treatment of Onychomycosis: Pros and Cons of Antifungal Agents. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 25-30.	0.6	18

#	ARTICLE	IF	CITATIONS
343	A Review of the Use of Infliximab to Manage Cutaneous Dermatoses. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 77-89.	0.6	27
344	Prednicarbate (Dermatop [®]): Profile of a Corticosteroid. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 244-249.	0.6	16
345	Pathogenesis of Psoriasis and Current Challenges. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 3-7.	0.6	10
346	Viral and Nonviral Uses of Imiquimod: A Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 338-352.	0.6	81
347	Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. <i>British Journal of Dermatology</i> , 2004, 150, 537-544.	1.4	144
348	Optimal Management of Fungal Infections of the Skin, Hair, and Nails. <i>American Journal of Clinical Dermatology</i> , 2004, 5, 225-237.	3.3	71
349	Role of Antifungal Agents in the Treatment of Seborrheic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2004, 5, 417-422.	3.3	84
350	Skin diseases associated with <i>Malassezia</i> species. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 785-798.	0.6	429
351	Fungus-free versus disease-free nails: Reply. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, 152-153.	0.6	3
352	Pityriasis versicolor: quality of studies. <i>Journal of Dermatological Treatment</i> , 2004, 15, 40-45.	1.1	2
353	Treatment of Onychomycosis: Pros and Cons of Antifungal Agents. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 25-30.	0.6	34
354	Prednicarbate (Dermatop [®]): Profile of a Corticosteroid. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 244-247.	0.6	7
355	Viral and Nonviral Uses of Imiquimod: A Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 338-352.	0.6	70
356	Onychomycosis: classification and diagnosis. <i>Journal of Drugs in Dermatology</i> , 2004, 3, 51-6.	0.4	31
357	Seborrheic dermatitis of the scalp: etiology and treatment. <i>Journal of Drugs in Dermatology</i> , 2004, 3, 155-8.	0.4	14
358	Management of onychomycosis: examining the role of monotherapy and dual, triple, or quadruple therapies. <i>Cutis</i> , 2004, 74, 5-9.	0.4	2
359	Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence. <i>Cutis</i> , 2004, 74, 10-5.	0.4	4
360	The use of sulfur in dermatology. <i>Journal of Drugs in Dermatology</i> , 2004, 3, 427-31.	0.4	69

#	ARTICLE	IF	CITATIONS
361	Ciclopirox (Loprox) gel for superficial fungal infections. <i>Skin Therapy Letter</i> , 2004, 9, 4-5, 9.	0.3	2
362	Ciclopirox shampoo for treating seborrheic dermatitis. <i>Skin Therapy Letter</i> , 2004, 9, 4-5.	0.3	16
363	Prednicarbate (dermatop): a review. <i>Journal of Drugs in Dermatology</i> , 2004, 3, 553-6.	0.4	3
364	A review of prednicarbate (Dermatop). <i>Skin Therapy Letter</i> , 2004, 9, 5-6, 9.	0.3	9
365	Onychomycosis: Quality of Studies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 312-316.	0.6	10
366	A Randomized, Double-Blind, Multicenter, Parallel Group Study to Compare Relative Efficacies of the Topical Gels 3% Erythromycin/5% Benzoyl Peroxide and 0.025% Tretinoin/Erythromycin 4% in the Treatment of Moderate Acne Vulgaris of the Face. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 31-37.	0.6	22
367	Comparison of efficacy criteria across onychomycosis trials: need for standardization. <i>International Journal of Dermatology</i> , 2003, 42, 312-315.	0.5	14
368	The diagnosis of nondermatophyte mold onychomycosis. <i>International Journal of Dermatology</i> , 2003, 42, 272-273.	0.5	29
369	Critical review of the manner in which the efficacy of therapies for rosacea are evaluated. <i>International Journal of Dermatology</i> , 2003, 42, 909-916.	0.5	13
370	Interdigital tinea pedis (dermatophytosis simplex and complex) and treatment with ciclopirox 0.77% gel. <i>International Journal of Dermatology</i> , 2003, 42, 23-27.	0.5	12
371	Ciclopirox for the treatment of superficial fungal infections: a review. <i>International Journal of Dermatology</i> , 2003, 42, 3-9.	0.5	39
372	Ciclopirox gel: an update. <i>International Journal of Dermatology</i> , 2003, 42, 1-2.	0.5	5
373	Arthroconidial formation in <i>Trichophyton raubitschekii</i> . <i>Arthrokonidienbildung bei Trichophyton raubitschekii</i> . <i>Mycoses</i> , 2003, 46, 304-310.	1.8	23
374	Fungal infections in immunocompromised patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2003, 17, 1-2.	1.3	32
375	The efficacy and safety of terbinafine in children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2003, 17, 627-640.	1.3	30
376	Pimecrolimus: A review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2003, 17, 493-503.	1.3	187
377	In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. <i>British Journal of Dermatology</i> , 2003, 149, 296-305.	1.4	138
378	Treatments of tinea pedis. <i>Dermatologic Clinics</i> , 2003, 21, 431-462.	1.0	41

#	ARTICLE	IF	CITATIONS
379	The use of fluconazole to treat superficial fungal infections in children. <i>Dermatologic Clinics</i> , 2003, 21, 537-542.	1.0	22
380	New antifungal agents. <i>Dermatologic Clinics</i> , 2003, 21, 565-576.	1.0	93
381	Non-dermatophyte onychomycosis. <i>Dermatologic Clinics</i> , 2003, 21, 257-268.	1.0	85
382	Oral antifungal drug interactions. <i>Dermatologic Clinics</i> , 2003, 21, 543-563.	1.0	9
383	Efficacy and safety of itraconazole use in children. <i>Dermatologic Clinics</i> , 2003, 21, 521-535.	1.0	39
384	How to improve cure rates for the management of onychomycosis. <i>Dermatologic Clinics</i> , 2003, 21, 499-505.	1.0	33
385	Superficial fungal infections: an update on pityriasis versicolor, seborrheic dermatitis, tinea capitis, and onychomycosis. <i>Clinics in Dermatology</i> , 2003, 21, 417-425.	0.8	87
386	The use of topical therapies to treat onychomycosis. <i>Dermatologic Clinics</i> , 2003, 21, 481-489.	1.0	51
387	Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. <i>Journal of Pediatrics</i> , 2003, 142, 155-162.	0.9	177
388	The use of oral antifungal agents to treat onychomycosis. <i>Dermatologic Clinics</i> , 2003, 21, 469-479.	1.0	39
389	Pityriasis versicolor. <i>Dermatologic Clinics</i> , 2003, 21, 413-429.	1.0	83
390	Evaluation of in vitro Resistance in Patients with Onychomycosis Who Fail Antifungal Therapy. <i>Dermatology</i> , 2003, 207, 375-380.	0.9	35
391	The efficacy and safety of terbinafine in children. <i>Dermatologic Clinics</i> , 2003, 21, 511-520.	1.0	32
392	Tinea corporis, tinea cruris, tinea nigra, and piedra. <i>Dermatologic Clinics</i> , 2003, 21, 395-400.	1.0	106
393	Seborrheic dermatitis. <i>Dermatologic Clinics</i> , 2003, 21, 401-412.	1.0	96
394	Photodynamic Therapy and Topical Aminolevulinic Acid. <i>American Journal of Clinical Dermatology</i> , 2003, 4, 699-708.	3.3	45
395	Psychiatric and Psychological Co-Morbidity in Patients with Dermatologic Disorders. <i>American Journal of Clinical Dermatology</i> , 2003, 4, 833-842.	3.3	284
396	A Randomized, Double-Blind, Multicenter, Parallel Group Study to Compare Relative Efficacies of the Topical Gels 3% Erythromycin/5% Benzoyl Peroxide and 0.025% Tretinoin/Erythromycin 4% in the Treatment of Moderate Acne Vulgaris of the Face. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 31-37.	0.6	27

#	ARTICLE	IF	CITATIONS
397	Evaluating the Quality of Rosacea Studies: Implications for the Patient and Physician. <i>Dermatology</i> , 2003, 207, 173-177.	0.9	3
398	Onychomycosis in children: an overview. <i>Journal of Drugs in Dermatology</i> , 2003, 2, 31-4.	0.4	11
399	Lustra, Lustra-AF and Alustra. <i>Skin Therapy Letter</i> , 2003, 8, 1-3.	0.3	0
400	Analysis of factors associated with increased prescription illegibility: results from the National Ambulatory Medical Care Survey, 1990-1998. <i>American Journal of Managed Care</i> , 2003, 9, 548-52.	0.8	7
401	Fungicidal activities of commonly used disinfectants and antifungal pharmaceutical spray preparations against clinical strains of <i>Aspergillus</i> and <i>Candida</i> species. <i>Medical Mycology</i> , 2002, 40, 201-208.	0.3	35
402	Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by <i>Fonsecaea pedrosoi</i> in Brazil. <i>Medical Mycology</i> , 2002, 40, 529-534.	0.3	97
403	Terbinafine in the Treatment of Trichophyton Tinea Capitis: A Randomized, Double-Blind, Parallel-Group, Duration-Finding Study. <i>Pediatrics</i> , 2002, 109, 602-607.	1.0	85
404	<i>Arachnomyces kanei</i> (anamorph <i>Onychocola kanei</i>) sp. nov., from human nails. <i>Medical Mycology</i> , 2002, 40, 573-580.	0.3	13
405	Imiquimod: A Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 554-560.	0.6	29
406	Efficacy of Itraconazole in the Prophylactic Treatment of Pityriasis (Tinea) Versicolor. <i>Archives of Dermatology</i> , 2002, 138, 69-73.	1.7	44
407	Use of Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Dermatologic Disorders. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 415-421.	0.6	73
408	Hepatic Safety of Itraconazole. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 210-213.	0.6	43
409	Dermatophytoma: Recalcitrance to treatment because of existence of fungal biofilm. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 629-631.	0.6	101
410	Management of toe onychomycosis: what is the potential for improving efficacy of treatment? Edited by Stephen P. Stone. <i>Clinics in Dermatology</i> , 2002, 20, 607-609.	0.8	5
411	Hepatic Safety of Itraconazole. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 210-213.	0.6	28
412	Use of Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Dermatologic Disorders. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 415-421.	0.6	20
413	Nonpsoriatic Uses of Calcipotriol. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 442-448.	0.6	5
414	Imiquimod: A Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 554-560.	0.6	53

#	ARTICLE	IF	CITATIONS
415	Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. <i>British Journal of Dermatology</i> , 2002, 147, 528-537.	1.4	239
416	Pityriasis versicolor. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2002, 16, 19-33.	1.3	121
417	Tacrolimus: a review of its use for the management of dermatoses. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2002, 16, 100-114.	1.3	92
418	Onychomycosis: strategies to improve efficacy and reduce recurrence. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2002, 16, 579-586.	1.3	35
419	Topical metronidazole for rosacea. <i>Skin Therapy Letter</i> , 2002, 7, 1-3, 6.	0.3	0
420	The management of actinic keratoses in the United States with topical fluorouracil: a pharmaco-economic evaluation. <i>Cutis</i> , 2002, 70, 30-6.	0.4	43
421	A survey of office visits for actinic keratosis as reported by NAMCS, 1990-1999. <i>National Ambulatory Medical Care Survey</i> . <i>Cutis</i> , 2002, 70, 8-13.	0.4	17
422	Itraconazole (Sporanox®) for vulvovaginal candidiasis. <i>Skin Therapy Letter</i> , 2002, 7 Suppl 1, 1-3.	0.3	1
423	Itraconazole (Sporanox®) for seborrheic dermatitis. <i>Skin Therapy Letter</i> , 2002, 7 Suppl 1, 4-5, 8.	0.3	0
424	Butenafine: an update of its use in superficial mycoses. <i>Skin Therapy Letter</i> , 2002, 7, 1-2, 5.	0.3	0
425	Are boosters or supplementation of antifungal drugs of any use for treating onychomycosis?. <i>Journal of Drugs in Dermatology</i> , 2002, 1, 35-41.	0.4	2
426	The use of the new oral antifungal agents, itraconazole, terbinafine, and fluconazole to treat onychomycosis and other dermatomycoses. <i>Current Problems in Dermatology</i> , 2001, 13, 213-246.	0.1	14
427	Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 485-491.	0.6	79
428	Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 479-484.	0.6	72
429	Epidemiology of <i>Malassezia</i> yeasts associated with pityriasis versicolor in Ontario, Canada. <i>Medical Mycology</i> , 2001, 39, 199-206.	0.3	119
430	Quantitative culture of <i>Malassezia</i> species from different body sites of individuals with or without dermatoses. <i>Medical Mycology</i> , 2001, 39, 243-251.	0.3	188
431	Comment & controversy. <i>Clinics in Dermatology</i> , 2001, 19, 360-363.	0.8	30
432	COMMON FUNGAL INFECTIONS. , 2001, , 42-56.		1

#	ARTICLE	IF	CITATIONS
433	Olanzapine May Be an Effective Adjunctive Therapy in the Management of <i>Acne Excoriata</i> : A Case Report. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 25-27.	0.6	24
434	Itraconazole and Terbinafine Treatment of Some Nondermatophyte Molds Causing Onychomycosis of the Toes and a Review of the Literature. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 206-210.	0.6	25
435	Itraconazole and Terbinafine Treatment of Some Nondermatophyte Molds Causing Onychomycosis of the Toes and a Review of the Literature. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 206-210.	0.6	51
436	Dissatisfaction with skin appearance among patients with eating disorders and non-clinical controls. <i>British Journal of Dermatology</i> , 2001, 145, 110-113.	1.4	49
437	Therapeutic Options for the Treatment of Tinea Capitis Caused by Trichophyton Species: Griseofulvin Versus the New Oral Antifungal Agents, Terbinafine, Itraconazole, and Fluconazole. <i>Pediatric Dermatology</i> , 2001, 18, 433-438.	0.5	133
438	Itraconazole is Effective in the Treatment of Tinea Capitis Caused by <i>Microsporum Canis</i> . <i>Pediatric Dermatology</i> , 2001, 18, 519-522.	0.5	32
439	Uncommon localization or presentation of tinea infection. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2001, 15, 7-8.	1.3	5
440	Itraconazole pulse therapy for the treatment of <i>Candida onychomycosis</i> . <i>Journal of the European Academy of Dermatology and Venereology</i> , 2001, 15, 112-115.	1.3	31
441	The use of antidepressant drugs in dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2001, 15, 512-518.	1.3	138
442	Ciclopirox: an overview. <i>International Journal of Dermatology</i> , 2001, 40, 305-310.	0.5	62
443	Efficacy of Itraconazole, Terbinafine, Fluconazole, Griseofulvin and Ketoconazole in the Treatment of <i>Scopulariopsis brevicaulis</i> Causing Onychomycosis of the Toes. <i>Dermatology</i> , 2001, 202, 235-238.	0.9	61
444	Utility of Inoculum Counting (Walshe and English Criteria) in Clinical Diagnosis of Onychomycosis Caused by Nondermatophytic Filamentous Fungi. <i>Journal of Clinical Microbiology</i> , 2001, 39, 2115-2121.	1.8	67
445	Variation in Restriction Fragment Length Polymorphisms among Serial Isolates from Patients with <i>Trichophyton rubrum</i> Infection. <i>Journal of Clinical Microbiology</i> , 2001, 39, 3260-3266.	1.8	35
446	Comparative efficacies of commonly used disinfectants and antifungal pharmaceutical spray preparations against dermatophytic fungi. <i>Medical Mycology</i> , 2001, 39, 321-328.	0.3	37
447	5-fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anterior scalp. <i>Skin Therapy Letter</i> , 2001, 6, 1-4.	0.3	3
448	Ciclopirox nail lacquer: a brush with onychomycosis. <i>Cutis</i> , 2001, 68, 13-6.	0.4	13
449	Types of onychomycosis. <i>Cutis</i> , 2001, 68, 4-7.	0.4	10
450	Open-Label Study to Evaluate the Healing Rate and Safety of the Profore [®] , [®] Extra Four-Layer Bandage System in Patients with Venous Leg Ulceration. <i>Journal of Cutaneous Medicine and Surgery</i> , 2000, 4, 8-11.	0.6	8

#	ARTICLE	IF	CITATIONS
451	Fusarium infections of the skin. <i>Current Opinion in Infectious Diseases</i> , 2000, 13, 121-128.	1.3	93
452	Dermatological complications. , 2000, 8, 134-143.		5
453	Detection of Xanthomegnin in Epidermal Materials Infected with <i>Trichophyton rubrum</i> . <i>Journal of Investigative Dermatology</i> , 2000, 115, 901-905.	0.3	40
454	The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2000, 14, 466-469.	1.3	119
455	Quality of life of psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2000, 14, 241-242.	1.3	36
456	In vitro susceptibility of the seven <i>Malassezia</i> species to ketoconazole, voriconazole, itraconazole and terbinafine. <i>British Journal of Dermatology</i> , 2000, 142, 758-765.	1.4	126
457	Once weekly fluconazole is effective in children in the treatment of tinea capitis: a prospective, multicentre study. <i>British Journal of Dermatology</i> , 2000, 142, 965-968.	1.4	58
458	Epidemiology and prevalence of onychomycosis in HIV-positive individuals. <i>International Journal of Dermatology</i> , 2000, 39, 746-753.	0.5	143
459	An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents. <i>International Journal of Dermatology</i> , 2000, 39, 401-411.	0.5	37
460	Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double-blind placebo-controlled study. <i>Journal of Dermatological Treatment</i> , 2000, 11, 33-37.	1.1	19
461	Evaluation of the in vitro and in vivo efficacy of butenafine hydrochloride cream 1% against <i>Malassezia furfur</i> species and seborrheic dermatitis. <i>Journal of Dermatological Treatment</i> , 2000, 11, 79-83.	1.1	6
462	Sequential pulse therapy with itraconazole and terbinafine to treat onychomycosis of the fingernails. <i>Journal of Dermatological Treatment</i> , 2000, 11, 151-154.	1.1	12
463	Tinea capitis. <i>Medical Mycology</i> , 2000, 38, 255-287.	0.3	152
464	Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. <i>Journal of the American Podiatric Medical Association</i> , 2000, 90, 495-501.	0.2	75
465	Ciclopirox nail lacquer and podiatric practice. <i>Journal of the American Podiatric Medical Association</i> , 2000, 90, 502-507.	0.2	8
466	The Implications and Management of Drug Interactions with Itraconazole, Fluconazole and Terbinafine. <i>Dermatology</i> , 2000, 201, 196-203.	0.9	31
467	Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: A multicenter Canadian survey of 15,000 patients. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 244-248.	0.6	329
468	A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 641-648.	0.6	453

#	ARTICLE	IF	CITATIONS
469	Ciclopirox nail lacquer solution 8% in the 21st century. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, S96-S102.	0.6	45
470	Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, S81-S95.	0.6	34
471	Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, S70-S80.	0.6	198
472	THE USE OF PSYCHOTROPIC DRUGS IN DERMATOLOGY. <i>Dermatologic Clinics</i> , 2000, 18, 711-725.	1.0	16
473	Onychomycosis in the Elderly. <i>Drugs and Aging</i> , 2000, 16, 397-407.	1.3	61
474	A Risk-Benefit Assessment of the Newer Oral Antifungal Agents Used to Treat Onychomycosis. <i>Drug Safety</i> , 2000, 22, 33-52.	1.4	76
475	Tinea manus treated with 1-week itraconazole vs. terbinafine. <i>International Journal of Dermatology</i> , 2000, 39, 529-531.	0.5	2
476	Tinea capitis. <i>Medical Mycology</i> , 2000, 38, 255-287.	0.3	9
477	Molecular Differentiation of Seven <i>Malassezia</i> Species. <i>Journal of Clinical Microbiology</i> , 2000, 38, 1869-1875.	1.8	106
478	The prevalence and management of onychomycosis in diabetic patients. <i>European Journal of Dermatology</i> , 2000, 10, 379-84.	0.3	85
479	Ciclopirox nail lacquer topical solution 8%. <i>Skin Therapy Letter</i> , 2000, 6, 1-5.	0.3	0
480	The Use of Itraconazole to Treat Cutaneous Fungal Infections in Children. <i>Dermatology</i> , 1999, 199, 248-252.	0.9	48
481	Safety review of the oral antifungal agents used to treat superficial mycoses. <i>International Journal of Dermatology</i> , 1999, 38, 40-52.	0.5	14
482	Intermittent short duration therapy with fluconazole is effective for tinea capitis. <i>British Journal of Dermatology</i> , 1999, 141, 304-306.	1.4	21
483	The use of intermittent itraconazole therapy for superficial mycotic infections: a review and update on the 'one week' approach. <i>International Journal of Dermatology</i> , 1999, 38, 28-39.	0.5	11
484	Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA. <i>International Journal of Dermatology</i> , 1999, 38, 53-64.	0.5	21
485	Erythroderma: a comparison between HIV positive and negative patients. <i>International Journal of Dermatology</i> , 1999, 38, 895-900.	0.5	64
486	Tinea Capitis: An Overview with Emphasis on Management. <i>Pediatric Dermatology</i> , 1999, 16, 171-189.	0.5	94

#	ARTICLE	IF	CITATIONS
487	The new oral antifungal agents for onychomycosis of the toenails. Journal of the European Academy of Dermatology and Venereology, 1999, 13, 1-13.	1.3	47
488	Drug interactions with itraconazole, fluconazole, and terbinafine and their management. Journal of the American Academy of Dermatology, 1999, 41, 237-249.	0.6	97
489	Combined distal and lateral subungual and white superficial onychomycosis in the toenails. Journal of the American Academy of Dermatology, 1999, 41, 938-944.	0.6	28
490	Safety of Itraconazole in Diabetic Patients. Dermatology, 1999, 198, 382-384.	0.9	25
491	The new oral antifungal agents for onychomycosis of the toenails. , 1999, 13, 1.		7
492	rRNA Gene Internal Transcribed Spacer 1 and 2 Sequences of Asexual, Anthropophilic Dermatophytes Related to <i>Trichophyton rubrum</i> . Journal of Clinical Microbiology, 1999, 37, 4005-4011.	1.8	97
493	Management of onychomycosis in children. Postgraduate Medicine, 1999, Spec No, 31-7.	0.9	0
494	Itraconazole oral solution for the treatment of tinea capitis using the pulse regimen. Cutis, 1999, 64, 192-4.	0.4	11
495	The new oral antifungal agents for onychomycosis of the toenails. Journal of the European Academy of Dermatology and Venereology, 1999, 13, 1-13.	1.3	6
496	Onychomycosis: predisposed populations and some predictors of suboptimal response to oral antifungal agents. European Journal of Dermatology, 1999, 9, 633-8.	0.3	23
497	Factors that may affect the response of onychomycosis to oral antifungal therapy. Australasian Journal of Dermatology, 1998, 39, 222-224.	0.4	39
498	Itraconazole for the treatment of onychomycosis. International Journal of Dermatology, 1998, 37, 303-308.	0.5	78
499	A questionnaire study on the management of onychomycosis: a Canadian perspective. International Journal of Dermatology, 1998, 37, 457-460.	0.5	10
500	Candida infection of the nail: role of Candida as a primary or secondary pathogen. International Journal of Dermatology, 1998, 37, 904-907.	0.5	33
501	Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. British Journal of Dermatology, 1998, 138, 529-532.	1.4	122
502	Itraconazole oral solution for the treatment of tinea capitis. British Journal of Dermatology, 1998, 139, 104-106.	1.4	31
503	Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. British Journal of Dermatology, 1998, 139, 665-671.	1.4	267
504	Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. British Journal of Dermatology, 1998, 139, 846-850.	1.4	768

#	ARTICLE	IF	CITATIONS
505	Itraconazole pulse therapy is effective in the treatment of Majocchi's granuloma: a clinical and pharmacokinetic evaluation and implications for possible effectiveness in tinea capitis. <i>Clinical and Experimental Dermatology</i> , 1998, 23, 103-108.	0.6	33
506	Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. <i>Clinical and Experimental Dermatology</i> , 1998, 23, 64-67.	0.6	54
507	Treatment of tinea capitis with itraconazole capsule pulse therapy. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, 216-219.	0.6	35
508	Severe neutropenia associated with oral terbinafine therapy. <i>Journal of the American Academy of Dermatology</i> , 1998, 38, 765-767.	0.6	51
509	The spectrum of cutaneous reactions associated with diltiazem: Three cases and a review of the literature. <i>Journal of the American Academy of Dermatology</i> , 1998, 38, 201-206.	0.6	79
510	Onychomycosis: An evaluation of three sampling methods. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, 1015-1017.	0.6	32
511	Onychomycosis associated with <i>Onychocola canadensis</i> : Ten case reports and a review of the literature. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, 410-417.	0.6	60
512	Oral antifungal agents for onychomycosis. <i>Lancet</i> , The, 1998, 351, 541-542.	6.3	34
513	Hypersensitivity syndrome reaction to oral terbinafine. <i>Australasian Journal of Dermatology</i> , 1998, 39, 171-172.	0.4	25
514	An Overview of Topical Antifungal Therapy in Dermatophytes. <i>Drugs</i> , 1998, 55, 645-674.	4.9	117
515	Pharmacoeconomic Analysis of Oral Antifungal Therapies Used to Treat Dermatophyte Onychomycosis of the Toenails. <i>Pharmacoeconomics</i> , 1998, 13, 243-256.	1.7	30
516	The Development of an Acne Quality of Life Scale: Reliability, Validity, and Relation to Subjective Acne Severity in Mild to Moderate Acne Vulgaris. <i>Acta Dermato-Venereologica</i> , 1998, 78, 451-456.	0.6	115
517	Heparin-Induced Thrombocytopenia. <i>Annals of Pharmacotherapy</i> , 1998, 32, 55-59.	0.9	30
518	Increased incidence of <i>Trichophyton tonsurans</i> tinea capitis in Ontario, Canada between 1985 and 1996. <i>Medical Mycology</i> , 1998, 36, 55-60.	0.3	72
519	Fluconazole for the treatment of onychomycosis: an update. <i>International Journal of Dermatology</i> , 1998, 37, 815-820.	0.5	15
520	Cigarette smoking and short-term treatment responsiveness of moderate to severe psoriasis. <i>Journal of Dermatological Treatment</i> , 1998, 9, 7-9.	1.1	1
521	Interaction between Terbinafine and Warfarin. <i>Dermatology</i> , 1998, 196, 266-267.	0.9	23
522	Terbinafine Pulse Therapy Is Effective in Tinea Capitis. <i>Pediatric Dermatology</i> , 1998, 15, 56-58.	0.5	1

#	ARTICLE	IF	CITATIONS
523	Itraconazole Pulse Therapy for Tinea Capitis: A Novel Treatment Schedule. <i>Pediatric Dermatology</i> , 1998, 15, 225-228.	0.5	8
524	PHARMACOLOGY AND THERAPEUTICS: Onychomycosis in Children: Prevalence and Management. <i>Pediatric Dermatology</i> , 1998, 15, 464-471.	0.5	15
525	Increased incidence of <i>Trichophyton tonsurans</i> tinea capitis in Ontario, Canada between 1985 and 1996. <i>Medical Mycology</i> , 1998, 36, 55-60.	0.3	14
526	Terbinafine pulse therapy is effective in tinea capitis.. <i>Pediatric Dermatology</i> , 1998, 15, 56-58.	0.5	31
527	A double-blind, randomized, placebo-controlled trial of eutectic lidocaine/prilocaine cream 5% (EMLA) for analgesia prior to cryotherapy of warts in children and adults.. <i>Pediatric Dermatology</i> , 1998, 15, 129-133.	0.5	35
528	Itraconazole pulse therapy for tinea capitis: a novel treatment schedule.. <i>Pediatric Dermatology</i> , 1998, 15, 225-228.	0.5	13
529	Onychomycosis in children: prevalence and management.. <i>Pediatric Dermatology</i> , 1998, 15, 464-471.	0.5	68
530	Itraconazole oral solution for the treatment of onychomycosis.. <i>Pediatric Dermatology</i> , 1998, 15, 472-474.	0.5	19
531	Increased incidence of <i>Trichophyton tonsurans</i> tinea capitis in Ontario, Canada between 1985 and 1996. <i>Medical Mycology</i> , 1998, 36, 55-60.	0.3	4
532	Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: an index of the stigma experience in dermatologic disorders. <i>Cutis</i> , 1998, 61, 339-42.	0.4	73
533	Increased incidence of <i>Trichophyton tonsurans</i> tinea capitis in Ontario, Canada between 1985 and 1996. <i>Medical Mycology</i> , 1998, 36, 55-60.	0.3	10
534	Itraconazole in the treatment of superficial cutaneous and mucosal <i>Candida</i> infections. <i>Journal of the American Osteopathic Association, The</i> , 1998, 98, 497-502.	1.7	6
535	Onychomycosis: strategies to reduce failure and recurrence. <i>Cutis</i> , 1998, 62, 189-91.	0.4	24
536	Multinational pharmaco-economic analysis of topical and oral therapies for onychomycosis. <i>Journal of Dermatological Treatment</i> , 1997, 8, 229-235.	1.1	9
537	The use of low-energy photon therapy in the treatment of leg ulcers – a preliminary study. <i>Journal of Dermatological Treatment</i> , 1997, 8, 103-108.	1.1	6
538	Calcipotriol in the Treatment of Psoriasis of Limited Severity: Pharmaco-economic Evaluation. <i>Journal of Cutaneous Medicine and Surgery</i> , 1997, 2, 7-15.	0.6	10
539	Pharmacoeconomics for Dermatologists: An Introduction. <i>Journal of Cutaneous Medicine and Surgery</i> , 1997, 1, 185-189.	0.6	0
540	CURRENT MANAGEMENT OF ONYCHOMYCOSIS. <i>Dermatologic Clinics</i> , 1997, 15, 121-135.	1.0	71

#	ARTICLE	IF	CITATIONS
541	ORAL ANTIFUNGAL DRUG INTERACTIONS. <i>Dermatologic Clinics</i> , 1997, 15, 535-544.	1.0	33
542	Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: Four case reports and a review of drug-induced psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 858-862.	0.6	96
543	Itraconazole pulse therapy for onychomycosis and dermatomycoses: An overview. <i>Journal of the American Academy of Dermatology</i> , 1997, 37, 969-974.	0.6	85
544	Terbinafine: An update. <i>Journal of the American Academy of Dermatology</i> , 1997, 37, 979-988.	0.6	104
545	Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: A multicenter study with 36 patients. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 173-177.	0.6	92
546	Onychomycosis in children: Prevalence and treatment strategies. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 395-402.	0.6	178
547	Hypersensitivity reaction to terbinafine. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 1018-1019.	0.6	38
548	Itraconazole for the treatment of tinea pedis: A dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 789-792.	0.6	28
549	Psoriasis and sex: a study of moderately to severely affected patients. <i>International Journal of Dermatology</i> , 1997, 36, 259-262.	0.5	148
550	Two feet-one hand syndrome: a retrospective multicenter survey. <i>International Journal of Dermatology</i> , 1997, 36, 658-660.	0.5	52
551	Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada - a multicenter survey of 2001 patients. <i>International Journal of Dermatology</i> , 1997, 36, 783-787.	0.5	184
552	Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicentre study. <i>British Journal of Dermatology</i> , 1997, 137, 251-254.	1.4	58
553	A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. <i>British Journal of Dermatology</i> , 1997, 136, 786-789.	1.4	46
554	A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. <i>British Journal of Dermatology</i> , 1997, 136, 786-789.	1.4	99
555	Onychomycosis. Going for cure. <i>Canadian Family Physician</i> , 1997, 43, 299-305.	0.1	9
556	A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. <i>British Journal of Dermatology</i> , 1997, 136, 786-9.	1.4	24
557	Psychological Factors Affecting Self-Excoriative Behavior in Women With Mild-to-Moderate Facial Acne Vulgaris. <i>Psychosomatics</i> , 1996, 37, 127-130.	2.5	36
558	Psychodermatology: An update. <i>Journal of the American Academy of Dermatology</i> , 1996, 34, 1030-1046.	0.6	258

#	ARTICLE	IF	CITATIONS
559	Clinical and Economic Factors in the Treatment of Onychomycosis. <i>Pharmacoeconomics</i> , 1996, 9, 307-320.	1.7	21
560	Photodamaged skin and quality of life: Reasons for therapy. <i>Journal of Dermatological Treatment</i> , 1996, 7, 261-264.	1.1	11
561	Economic Evaluation of Antifungal Agents in the Treatment of Toenail Onychomycosis in Germany. <i>Dermatology</i> , 1996, 193, 239-244.	0.9	38
562	Cigarette smoking in men may be a risk factor for increased severity of psoriasis of the extremities. <i>British Journal of Dermatology</i> , 1996, 135, 859-860.	1.4	46
563	Peripheral Edema Due to Nifedipine-Itraconazole Interaction: A Case Report. <i>Archives of Dermatology</i> , 1996, 132, 350.	1.7	4
564	Peripheral edema due to nifedipine-itraconazole interaction: a case report. <i>Archives of Dermatology</i> , 1996, 132, 350-352.	1.7	47
565	The use of high-frequency ultrasound as a method of assessing the severity of a plaque of psoriasis. <i>Archives of Dermatology</i> , 1996, 132, 658-662.	1.7	34
566	The development of green vision in association with terbinafine therapy. <i>Archives of Dermatology</i> , 1996, 132, 845-846.	1.7	20
567	Onychomycosis. New therapies for an old disease. <i>Western Journal of Medicine</i> , 1996, 165, 349-51.	0.3	3
568	The use of high-frequency ultrasound as a method of assessing the severity of a plaque of psoriasis. <i>Archives of Dermatology</i> , 1996, 132, 658-62.	1.7	9
569	Nondermatophyte causes of onychomycosis and superficial mycoses. <i>Current Topics in Medical Mycology</i> , 1996, 7, 87-97.	0.8	33
570	Early onset (< 40 years age) psoriasis is comorbid with greater psychopathology than late onset psoriasis: a study of 137 patients.. <i>Acta Dermato-Venereologica</i> , 1996, 76, 464-466.	0.6	27
571	Terbinafine: An alternative treatment for tinea faciei. <i>Journal of Dermatological Treatment</i> , 1995, 6, 187-188.	1.1	0
572	Application of a eutectic mixture of lidocaine/prilocaine cream to the moustache area prior to electrolysis provides effective analgesia. <i>Journal of Dermatological Treatment</i> , 1995, 6, 89-94.	1.1	5
573	TERBINAFINE IN THE TREATMENT OF MAJOCCHI'S GRANULOMA. <i>International Journal of Dermatology</i> , 1995, 34, 489-489.	0.5	39
574	AGE AND GENDER DIFFERENCES IN THE IMPACT OF PSORIASIS ON QUALITY OF LIFE. <i>International Journal of Dermatology</i> , 1995, 34, 700-703.	0.5	121
575	Azathioprine hypersensitivity-like reactions-a case report and a review of the literature. <i>Clinical and Experimental Dermatology</i> , 1995, 20, 353-356.	0.6	131
576	Lithium therapy associated with hidradenitis suppurativa: Case report and a review of the dermatologic side effects of lithium. <i>Journal of the American Academy of Dermatology</i> , 1995, 32, 382-386.	0.6	72

#	ARTICLE	IF	CITATIONS
577	Perceived touch deprivation and body image: some observations among eating disordered and non-clinical subjects. <i>Journal of Psychosomatic Research</i> , 1995, 39, 459-464.	1.2	30
578	Chronic idiopathic urticaria associated with panic disorder: a syndrome responsive to selective serotonin reuptake inhibitor antidepressants?. <i>Cutis</i> , 1995, 56, 53-4.	0.4	16
579	Terbinafine for the treatment of pedal onychomycosis. A foot closer to the promised land of cured nails?. <i>Archives of Dermatology</i> , 1995, 131, 937-42.	1.7	7
580	PSYCHOSOMATIC STUDY OF SELF-EXCORIATIVE BEHAVIOR AMONG MALE ACNE PATIENTS: PRELIMINARY OBSERVATIONS. <i>International Journal of Dermatology</i> , 1994, 33, 846-848.	0.5	32
581	EPIDERMOLYSIS BULLOSA ACQUISITA WITH FEATURES OF BULLOUS LUPUS ERYTHEMATOSUS. <i>International Journal of Dermatology</i> , 1994, 33, 192-195.	0.5	8
582	Antifungal agents: An overview. Part II. <i>Journal of the American Academy of Dermatology</i> , 1994, 30, 911-933.	0.6	252
583	Antifungal agents: An overview. Part I. <i>Journal of the American Academy of Dermatology</i> , 1994, 30, 677-698.	0.6	181
584	Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria.. <i>Psychosomatic Medicine</i> , 1994, 56, 36-40.	1.3	262
585	Antifungal agents: an overview. Part I. <i>Journal of the American Academy of Dermatology</i> , 1994, 30, 677-98; quiz 698-700.	0.6	38
586	BETAMETHASONE DIPROPIONATE POLYACRYLIC FILM-FORMING LOTION IN THE TREATMENT OF HAND DERMATITIS. <i>International Journal of Dermatology</i> , 1993, 32, 828-829.	0.5	16
587	DERMATITIS ARTEFACTA AND SEXUAL ABUSE. <i>International Journal of Dermatology</i> , 1993, 32, 825-826.	0.5	34
588	SUICIDAL IDEATION IN PSORIASIS. <i>International Journal of Dermatology</i> , 1993, 32, 188-190.	0.5	233
589	Alcohol intake and treatment responsiveness of psoriasis: A prospective study. <i>Journal of the American Academy of Dermatology</i> , 1993, 28, 730-732.	0.6	131
590	Fluoxetine is an effective treatment for neurotic excoriations: case report. <i>Cutis</i> , 1993, 51, 386-7.	0.4	19
591	Bulimia Nervosa and Acne May be Related: A Case Report*. <i>Canadian Journal of Psychiatry</i> , 1992, 37, 58-61.	0.9	18
592	Starvation-associated pruritus: A clinical feature of eating disorders. <i>Journal of the American Academy of Dermatology</i> , 1992, 27, 118-120.	0.6	14
593	Verapamil prevents insulin antinatriuresis in euglycemic rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1992, 262, R1145-R1148.	0.9	2
594	Effects of insulin on renal sodium excretion.. <i>Hypertension</i> , 1992, 19, 178-82.	1.3	66

#	ARTICLE	IF	CITATIONS
595	Short-term Changes in Renal Function, Blood Pressure, and Electrolyte Levels in Patients Receiving Cyclosporine for Dermatologic Disorders. Archives of Internal Medicine, 1991, 151, 356.	4.3	26
596	Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders. Archives of Internal Medicine, 1991, 151, 356-362.	4.3	6
597	Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders. Archives of Internal Medicine, 1991, 151, 356-62.	4.3	5
598	Psychiatric Aspects of the Treatment of Mild to Moderate Facial Acne.. International Journal of Dermatology, 1990, 29, 719-721.	0.5	72
599	Oral cyclosporine for the treatment of alopecia areata. Journal of the American Academy of Dermatology, 1990, 22, 242-250.	0.6	186
600	Effects of cyclosporine on immunologic mechanisms in psoriasis. Journal of the American Academy of Dermatology, 1990, 23, 1318-1328.	0.6	40
601	Treatment of severe lichen planus with cyclosporine. Journal of the American Academy of Dermatology, 1990, 22, 64-68.	0.6	100
602	Lymphocytic infiltrates of the skin in association with cyclosporine therapy. Journal of the American Academy of Dermatology, 1990, 23, 1137-1141.	0.6	21
603	Intralesional cyclosporine in the treatment of psoriasis. Journal of the American Academy of Dermatology, 1990, 22, 94-100.	0.6	98
604	Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Archives of Dermatology, 1990, 126, 339-350.	1.7	146
605	Sulfasalazine improves psoriasis. A double-blind analysis. Archives of Dermatology, 1990, 126, 487-493.	1.7	62
606	Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Archives of Dermatology, 1990, 126, 339-50.	1.7	24
607	Psoriatic Epidermal Cells Demonstrate Increased Numbers and Function of Non-Langerhans Antigen-presenting Cells. Journal of Investigative Dermatology, 1989, 92, 190-195.	0.3	101
608	Topical Cyclosporine A Inhibits the Phorbol Ester Induced Hyperplastic Inflammatory Response but not Protein Kinase C Activation in Mouse Epidermis.. Journal of Investigative Dermatology, 1989, 93, 379-386.	0.3	40
609	Side-effect profile of acitretin therapy in psoriasis. Journal of the American Academy of Dermatology, 1989, 20, 1088-1093.	0.6	114
610	Cyclosporine A. Clinics in Dermatology, 1989, 7, 98-110.	0.8	9
611	Pruritus associated with nocturnal awakenings: Organic or psychogenic?. Journal of the American Academy of Dermatology, 1989, 21, 479-484.	0.6	23
612	A psychocutaneous profile of psoriasis patients who are stress reactors. General Hospital Psychiatry, 1989, 11, 166-173.	1.2	134

#	ARTICLE	IF	CITATIONS
613	Topical cyclosporine A inhibits the phorbol ester induced hyperplastic inflammatory response but not protein kinase C activation in mouse epidermis. <i>Journal of Investigative Dermatology</i> , 1989, 93, 379-386.	0.3	24
614	Papular midfacial eruption in a child. Cutaneous Sarcoidosis. <i>Archives of Dermatology</i> , 1989, 125, 1704-1705.	1.7	3
615	Cyclosporine in the treatment of psoriatic arthritis. <i>Archives of Dermatology</i> , 1989, 125, 507-510.	1.7	50
616	Topical cyclosporine A inhibits the phorbol ester induced hyperplastic inflammatory response but not protein kinase C activation in mouse epidermis. <i>Journal of Investigative Dermatology</i> , 1989, 93, 379-86.	0.3	7
617	Sphingosine Inhibits Phorbol Ester-Induced Inflammation, Ornithine Decarboxylase Activity, and Activation of Protein Kinase C in Mouse Skin. <i>Journal of Investigative Dermatology</i> , 1988, 91, 486-491.	0.3	95
618	Acitretin improves psoriasis in a dose-dependent fashion. <i>Journal of the American Academy of Dermatology</i> , 1988, 18, 655-662.	0.6	116
619	Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. <i>Archives of Dermatology</i> , 1988, 124, 1052-1057.	1.7	127
620	Psoriasis and psychiatry: An update. <i>General Hospital Psychiatry</i> , 1987, 9, 157-166.	1.2	74
621	The self-inflicted dermatoses: A critical review. <i>General Hospital Psychiatry</i> , 1987, 9, 45-52.	1.2	112
622	Effect of steroid ingestion on pancreatic echogenicity. <i>Journal of Clinical Ultrasound</i> , 1987, 15, 171-174.	0.4	5
623	Neurotic excoriations: A review and some new perspectives. <i>Comprehensive Psychiatry</i> , 1986, 27, 381-386.	1.5	91
624	Psychotropic drugs in dermatology. <i>Journal of the American Academy of Dermatology</i> , 1986, 14, 633-645.	0.6	39
625	Perioral Dermatitis. , 0, , 111-116.		1
626	Actinic Keratoses and Bowen's Disease. , 0, , 294-314.		0
627	Onychomycosis. , 0, , 362-385.		0